WC
PRNB

Weil Company’s Principia Biopharma Inc. Common Stock PRNB Stock Holding History

Weil Company’s Portfolio PRNB Stock Details PRNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-163
Closed -$5K – 384
2019
Q3 		$5K Buy
+163
New +$5.98K ﹤0.01% 345

Other funds holding PRNB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Weil Company's PRNB Position: Q4 2019 in Review

Weil Company sold out of Principia Biopharma Inc. Common Stock (PRNB) in Q4 2019, closing a stake of 163 shares — an estimated $5K sold.

Weil Company first reported a position in PRNB in Q3 2019 and held it in 1 quarter. The position peaked at $5K in Q3 2019. 115 funds tracked by Wall St. Rank hold PRNB as of Q4 2019.

  • Weil Company reported no remaining Principia Biopharma Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Weil Company sold 163 Principia Biopharma Inc. Common Stock shares in Q4 2019, an estimated $5K.
  • Weil Company first reported a position in Principia Biopharma Inc. Common Stock in Q3 2019 and held it in 1 quarter.
  • Weil Company's Principia Biopharma Inc. Common Stock position peaked at $5K in Q3 2019.
  • 115 funds tracked by Wall St. Rank held Principia Biopharma Inc. Common Stock as of Q4 2019.

Based on Weil Company's 13F filing for Q4 2019, filed 13 Feb 2020.